Clinical utility of serum biomarkers in Duchenne muscular dystrophy-Reference-Cited by-同舟云学术

Clinical utility of serum biomarkers in Duchenne muscular dystrophy

Published:2016-04-05 Issue:1 Volume:13 Page:
ISSN:1542-6416
Container-title:Clinical Proteomics
language:en
Short-container-title:Clin Proteom

Author:

Hathout Yetrib,Seol Haeri,Han Meng Hsuan J.,Zhang Aiping,Brown Kristy J.,Hoffman Eric P.

Funder

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Congressionally Directed Medical Research Programs

Muscular Dystrophy Association

AFM-Téléthon

Foundation to Eradicate Duchenne

Clark Charitable Foundation

National Institute of Child Health and Human Development

Publisher

Springer Science and Business Media LLC

Subject

Clinical Biochemistry,Molecular Biology,Molecular Medicine,Clinical Biochemistry,Molecular Biology,Molecular Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12014-016-9109-x.pdf

Reference56 articles.

1. Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 2014;24:482–91.

2. Stark AE. Determinants of the incidence of Duchenne muscular dystrophy. Ann Transl Med. 2015;3:287.

3. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919–28.

4. Ervasti JM, Campbell KP. Membrane organization of the dystrophin–glycoprotein complex. Cell. 1991;66:1121–31.

5. Ervasti JM, Campbell KP. Dystrophin-associated glycoproteins: their possible roles in the pathogenesis of Duchenne muscular dystrophy. Mol Cell Biol Hum Dis Ser. 1993;3:139–66.

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies – Developing Potential Treatments for the Entire Spectrum of Disease;Journal of Neuromuscular Diseases;2024-03-05

2. N-terminal titin fragment: a non-invasive, pharmacodynamic biomarker for microdystrophin efficacy;Skeletal Muscle;2024-01-16

3. Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers;Clinical Proteomics;2023-06-12

4. A Proof of Principle Proteomic Study Detects Dystrophin in Human Plasma: Implications in DMD Diagnosis and Clinical Monitoring;International Journal of Molecular Sciences;2023-03-08

5. Orthogonal proteomics methods warrants development of Duchenne Muscular Dystrophy biomarkers;2022-12-05